The effect of Obstructive Sleep Apnoea (OSA) and its treatment with Continuous Positive Airways Pressure (CPAP) on lipid metabolism

Not Applicable

Completed

• Conditions: Obstructive Sleep Apnoea (OSA); Respiratory - Sleep apnoea

• Registration Number: ACTRN12605000066684
• Lead Sponsor: Woolcock Institute of Medical Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-08-02
• Study Completion: 2009-09-30
• Last Update Posted: 9 August 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 29

Inclusion Criteria

Body Mass Index (BMI) less than or equal to 35. Fasting Triglycerides < 4mmol/L. Respiratory Disturbance Index (RDI) of >= 25 and Oxygen Desaturation Index (ODI) >=20

Exclusion Criteria

Stage 1 1. Clinically significant co morbidity, including any unstable cardiovascular, gastrointestinal, metabolic, pulmonary (e.g., asthma, COPD), renal, neurological, hepatic, hematologic, immunologic, endocrine, psychiatric illness and/or neoplastic disease based on Principal Investigator judgment. 2. Patients who are on fibrate (lipid lowering) medications. 3. Fasting triglycerides > 4mmol/l 4. Patients unable to read and understand the Patient Information Sheets or Consent Forms. Stage 2 1. Claustrophobia. 2. Any in vivo Ferro-magnetic material such as a pacemaker, Neuro stimulator, Cochlear Implants, aneurysm clip, metal implants, shrapnel injuries, ever worked with metal, ever had metal in their eye or if they had any surgery.
Stage 3 1. Clinically significant co morbidity, including any unstable cardiovascular, gastrointestinal, metabolic, pulmonary (e.g., asthma, COPD), renal, neurological, hepatic, hematologic, immunologic, endocrine, psychiatric illness and/or neoplastic disease based on Principal Investigator judgment. 2. Patients unable to read and understand the Patient Information Sheets or Consent Forms. 3. Medication exclusions - Beta blockers and Beta 2 agonists.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Total Area under the Triglyceride concentration curve (AUC) over 24 hours.[at Baseline and at 2 months after each of CPAP or Sham CPAP]

Secondary Outcome Measures

Name	Time	Method
Arterial Stiffness ? Aortic Augmentation Index[at Baseline and at 2 months after each of CPAP or Sham CPAP];Hepatocellular Lipid Concentration[at Baseline and at 2 months after each of CPAP or Sham CPAP];Visceral and Subcutaneous Abdominal Fat[at Baseline and at 2 months after each of CPAP or Sham CPAP];Oxidative stress markers[at Baseline and at 2 months after each of CPAP or Sham CPAP]